Basic fibroblast growth factor promotes bone ingrowth in porous hydroxyapatite.
The effect of basic fibroblast growth factor on tissue ingrowth and differentiation in porous hydroxyapatite of coralline origin was studied in a bone chamber model. The hydroxyapatite with or without basic fibroblast growth factor was placed in 22 mm3 titanium bone conduction chambers implanted bilaterally in rat tibiae. Ingrowing bone could enter the cylindrical interior of the chamber only at 1 end. It then penetrated the porous hydroxyapatite inside the chamber. The distance that the ingrown tissue had reached into the material then was measured on histologic slides. Because fibrous tissue always reached further into the material than did bone, both total tissue ingrowth and bone ingrowth distances were measured. In implants supplemented with 0.04 microg basic fibroblast growth factor in a hyaluronate gel carrier, the bone ingrowth distance was increased by 70% at 6 weeks, as compared with paired controls in the contralateral leg. The total tissue ingrowth distance also was increased by 58%. When the dose of basic fibroblast growth factor was increased to 1.0 microg, still using the hyaluronate carrier, there was no difference in bone ingrowth compared with controls, but this dose still increased the total tissue ingrowth. In hydroxyapatite with 1.5 microg basic fibroblast growth factor without hyaluronate gel at 4 weeks, no increase in bone ingrowth was shown, but total tissue ingrowth was increased. At 6 weeks, bone ingrowth and total tissue ingrowth were increased by 41% and 33%, respectively. With a lower dose of 0.15 microg without carrier, only the total ingrowth distance was increased. The results suggest that basic fibroblast growth factor may promote tissue ingrowth into porous hydroxyapatite and that bone ingrowth may be increased by appropriate doses. The hyaluronate gel carrier reduced the optimal dose.
Wang
J S
JS
Department of Orthopedics, Lund University Hospital, Sweden.
Aspenberg
P
P
D000818:Animals; D018786:Bone Substitutes / Q000627:therapeutic use; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D006882:Hydroxyapatites / Q000627:therapeutic use; D008297:Male; D016348:Osseointegration / Q000187:drug effects*; D019736:Prostheses and Implants; D051381:Rats; D017207:Rats, Sprague-Dawley
D018786:Bone Substitutes; D004337:Drug Carriers; D006882:Hydroxyapatites; D016222:Fibroblast Growth Factor 2